Tech Company Financing Transactions
Exai Bio Funding Round
Exai Bio, based in Palo Alto, raised $67.5 million from Casdin Capital, Section 32 and Two Sigma Ventures.
Transaction Overview
Company Name
Announced On
12/10/2021
Transaction Type
Venture Equity
Amount
$67,500,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
3550 West Bayshore Rd.
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pat Arensdorf
Chief Scientific Officer
Babak Alipanahi
VP - Administration
Nelson Lee
VP - Engineering
Helen Li
VP - Operations
Kim Chau
VP - R & D
Lisa Fish
Browse more venture capital transactions:
Prev: 12/10/2021: Blickfeld venture capital transaction
Next: 12/10/2021: Palm NFT Studio venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs